Wegovy and MASH: what does the new UK licence actually cover?

What exactly is MASH, and why does this approval matter?

MASH stands for metabolic dysfunction-associated steatohepatitis. It sits on a spectrum of liver conditions that begins with fat accumulation in liver cells (steatosis) and, in some people, progresses to inflammation and cell injury, that's the steatohepatitis part. At the more serious end of the spectrum, sustained inflammation leads to fibrosis: the gradual replacement of healthy liver tissue with scar tissue. Advanced fibrosis can tip into cirrhosis, liver failure, or hepatocellular carcinoma.

Until July 2026, there was no medicine specifically authorised in the UK to treat this stage of the disease. Management relied on lifestyle changes, treating underlying metabolic conditions, and monitoring. The MHRA's conditional approval of semaglutide for MASH, confirmed by the government's official announcement on 3 July 2026, changes that. It is the first pharmacological treatment licensed for MASH with moderate-to-advanced fibrosis in the UK, which is why it has attracted significant attention from hepatologists and metabolic medicine specialists.

The term MASH itself is relatively recent; you may have seen older clinical notes or news coverage referring to NASH (non-alcoholic steatohepatitis). The nomenclature shifted in 2023 to better reflect the metabolic origins of the condition. They describe the same disease process.

Who is the Wegovy MASH licence actually for?

The conditional approval is specific: it covers adults with MASH who have moderate-to-advanced liver fibrosis. This is not a broad licence for anyone with fatty liver, and it is separate from Wegovy's weight-management authorisation (BMI ≥30, or ≥27 with a weight-related condition).

In practice, this means the MASH indication is a specialist clinical territory. A gastroenterologist or hepatologist would typically be involved in confirming the diagnosis and staging of fibrosis (often via biopsy or non-invasive assessment tools) before treatment under this licence would be considered. The prescribing decision sits with the clinician managing the liver condition, and the conditional nature of the approval means that manufacturers are required to submit ongoing safety and efficacy data to the MHRA.

Patients who are already taking Wegovy for weight management and also have a MASH diagnosis should discuss both conditions with their treating team rather than assuming their current treatment covers both indications automatically. You can find fuller background on semaglutide's properties and licensed uses on our semaglutide overview page.

It's also worth noting that Wegovy already holds a third UK authorisation, for reducing major cardiovascular event risk in eligible adults. This makes semaglutide one of the few medicines in the UK with three distinct licensed indications, each carrying its own patient criteria.

What does the trial evidence behind the MASH approval look like?

The MHRA's conditional approval was based on clinical trial data showing that semaglutide produced meaningful improvements in liver histology, specifically, reductions in liver inflammation and, in some participants, regression of fibrosis stage. The approval is described as conditional because longer-term data are still being gathered; this is standard regulatory practice when the available evidence is promising but the follow-up period is not yet complete.

For broader context on semaglutide's efficacy profile, the STEP 1 trial (published in the New England Journal of Medicine) established around 15% average body-weight reduction at the 2.4mg weekly maintenance dose over 68 weeks in adults with obesity. Weight reduction itself is considered mechanistically relevant to MASH, since excess adiposity drives hepatic fat accumulation and inflammation. The MASH trial data go beyond weight loss, however, looking directly at liver tissue changes as the primary endpoint.

If you are researching this topic because you or someone close to you has a MASH diagnosis, our page on semaglutide for MASH goes deeper into the evidence and clinical pathway, and the UK MASH approval explainer covers the regulatory detail.

Does this change anything for people using Wegovy for weight loss?

For most people currently using, or considering, Wegovy for weight management, the MASH approval does not alter the treatment path. The weight-loss licence remains exactly as it was: Wegovy is prescribed for adults meeting BMI thresholds, alongside a reduced-calorie diet and increased physical activity, reviewed by a prescriber before each supply.

One practical area worth mentioning: because Wegovy's mechanism does appear to influence liver fat and inflammation, some people with both obesity and a MASH diagnosis may find the two conditions are being considered together by their clinical team. That is a conversation to have with the prescribers and specialists involved in your care, not something to navigate alone. Side effects are the same across indications (predominantly gastrointestinal at the start of treatment) and the usual monitoring applies.

If you're exploring what weight-management treatment might look like for you more broadly, our Wegovy overview covers the full weight-loss picture, and you can see how treatment costs compare across the private market on our Wegovy cost page. Questions about muscle mass during treatment are answered on our page on Wegovy and muscle mass. When you're ready to speak to a prescriber, check your eligibility and start a free consultation with our clinical team.